An Open Label Study to Determine ADME of [14C] labeled SLV334 and its Metabolites after Single Intravenous Dose Infusion.

An Open Label Study to Determine ADME of [14C] labeled SLV334 and its Metabolites after Single Intravenous Dose Infusion. - SLV334 ADME study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON34670

Enrollment

Registered

2010-02-04

Start date

2010-03-15

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Traumatische hersenbeschadiging Brain injury Therapy

Interventions

Active substance: SLV334

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Healthy male - 18-55 years of age, inclusive - BMI 18.0 - 28.0 kg/m2 (weight between 50 and 100 kg inclusive) - non-smoker

Exclusion criteria

Exclusion criteria: Suffering from: hepatitis B, cancer or HIV/AIDS. In case of participation in another drug study within 90 days before the start of this study or being a blood donor within 60 days from the start of the study. In case of donating more than 1.5 liters of blood in the 10 months prior the start of this study.

Design outcomes

Primary

Measure	Time frame
Radiodynamics Pharmacokinetics Safety	—

Secondary

Measure	Time frame
n.a.	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)